Skip to content

Effect of syntocinone (active ingredient: oxytocin) on neuronal processing of alcohol stimuli

Effect of syntocinone (active ingredient: oxytocin) on neuronal processing of alcohol stimuli - Target-OXY-MRI

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026218
Enrollment
54
Registered
2021-09-08
Start date
2021-09-09
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder (DSM-5)

Interventions

Group 1: Crossover design, randomized, double-blind: Participants take part in a cue exposure with their favorite alcoholic beverage. Alcohol craving will be assessed with the Alcohol Urge Questionnai

Sponsors

Zentralinstitut für Seelische Gesundheit
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years; ability to give fully informed consent and to undergo functional magnetic resonance imaging; written informed consent; diagnosis of alcohol use disorder according to DSM-5 (min. 2 AUD criteria).

Exclusion criteria

Exclusion criteria: Pregnancy or lactation; presence of severe heart disease or long QT syndrome; participants 65 years of age; psychosis or other severe psychiatric disorder; severe internistic and neurological comorbidities; use of psychotropic medication other than antidepressants from the group of serotonin reuptake inhibitors (SSRI) or mirtazapine and of pipamperone; Current drug abuse of amphetamines, opiates, benzodiazepines, and cocaine (urine drug screening); Contraindication to functional magnetic resonance imaging.

Design outcomes

Primary

MeasureTime frame
cue-reactivity (fMRI)

Secondary

MeasureTime frame
Alcohol Urge Questionnaire (repeated measurement; sum scores) depressive symptoms (BDI-II sum score) anxiety (STAI sum score) perceived stress (Perceived Stress Scale sum score) personality (NEO-FFI sum score, only compared between subjects) biomaterials - oxytocin plasma level - cortisol level (saliva) - inflammation markers - appetite- and volume markers (leptine, ghrelin)

Countries

Germany

Contacts

Public ContactSina Zimmermann

Zentralinstitut für seelische Gesundheit

sina.zimmermann@zi-mannheim.de0621 1703-3919

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026